HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy
Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdominal Radiology 2021, 46: 3686-3697. PMID: 34195886, DOI: 10.1007/s00261-021-03192-8.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaTumor biologyHCC tumor biologyRare responsesTreatment hepatocellular carcinomaPost-treatment responsePrognostic featuresAbscopal effectAdverse outcomesCancer deathIdeal therapyEffective therapyImaging featuresDisease evolveIndividual patientsLiver cancerMore therapiesTumor behaviorTreatment planParticular tumorTherapyClinical useTreatment planningPatientsTumorsHepatocellular carcinoma: metastatic pathways and extra-hepatic findings
Arora S, Harmath C, Catania R, Mandler A, Fowler KJ, Borhani AA. Hepatocellular carcinoma: metastatic pathways and extra-hepatic findings. Abdominal Radiology 2021, 46: 3698-3707. PMID: 34091729, DOI: 10.1007/s00261-021-03151-3.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaExtrahepatic diseaseMetastatic diseaseManagement of patientsEarly metastatic diseaseCourse of treatmentExtrahepatic spreadDefinitive treatmentInitial presentationTreatment optionsPrecise stagingMetastatic pathwaysTumor biologySystemic spreadMolecular derangementsPatientsDiseasePotential roleDifferent pathwaysMolecular characteristicsTreatmentPathwayCarcinomaDerangementStaging